First-in-human phase I study of anti-HER2 ADC MRG002 in patients with relapsed/refractory solid tumors.

Jin Li,Y. Guo,Junli Xue,Wei Peng,Xiaoxiao Ge,Wei Zhao,Congqi Dai,Liqiong Xue,Wenbo Tang,Chaohong Hu

First-in-human phase I study of anti-HER2 ADC MRG002 in patients with relapsed/refractory solid tumors.

2020

Jin Li
Y. Guo
Junli Xue
Wei Peng
Xiaoxiao Ge
Wei Zhao
Congqi Dai
Liqiong Xue
Wenbo Tang
Chaohong Hu

TPS1101Background: MRG002 is an antibody drug conjugate (ADC) composed of a humanized anti-HER2 IgG1 monoclonal antibody conjugated to a microtubule disrupting agent monomethyl auristatin E (MMAE)....

Keywords:

Oncology
first in human
phase i study
in patient
Internal medicine
Pathology
anti her2
Medicine
relapsed refractory
Monomethyl auristatin E
Cancer research
Monoclonal antibody
Antibody-drug conjugate

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations